EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CAR T-cells for pediatric solid tumors: where to go from here?

Tina Trautmann, Natalia Yakobian, Rosa Nguyen

Cancer and Metastasis Reviews · 2024

DOI: 10.1007/s10555-024-10214-6 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer and Metastasis Reviews, 2024. Verfasst von Tina Trautmann und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Oncology Branch, NCI, NIH, NCI, 10 Center Drive, 1W-5832, Bethesda, MD, 20892, USA. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, T-Lymphocytes. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 183 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, CCR NIH HHS, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the great success that chimeric antigen receptor (CAR) T-cells have had in patients with B-cell malignancies and multiple myeloma, they continue to have limited efficacy against most solid tumors. Especially in the pediatric population, pre- and post-treatment biopsies are rarely performed due to ethical reasons, and thus, our understanding is still very limited regarding the mechanisms in the tumor microenvironment by which tumor cells exclude effectors and attract immune-suppressive cells. Nevertheless, based on the principles that are known, current T-cell engineering has leveraged some of these processes and created more potent CAR T-cells. The recent discovery of new oncofetal antigens and progress made in CAR design have expanded the potential pool of candidate antigens for therapeutic development. The most promising approaches to enhance CAR T-cells are novel CAR gating strategies, creative ways of cytokine delivery to the TME without enhancing systemic toxicity, and hijacking the chemokine axis of tumors for migratory purposes. With these new modifications, the next step in the era of CAR T-cell development will be the clinical validation of these promising preclinical findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesHumansChildTumor MicroenvironmentAnimalsReceptors, Antigen, T-Cell

Stichwörter der Autor:innen

Adoptive T-cell therapyCARPediatric oncologySolid tumors

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Pediatric Oncology Branch, NCI, NIH, NCI, 10 Center Drive, 1W-5832, Bethesda, MD, 20892, USA.
  • Pediatric Oncology Branch, NCI, NIH, NCI, 10 Center Drive, 1W-5832, Bethesda, MD, 20892, USA. hongharosa.nguyen@nih.gov.

Förderung

  • Intramural NIH HHS
  • CCR NIH HHS
  • Deutsche Forschungsgemeinschaft
  • Center for Cancer Research
  • Children's Cancer Foundation
  • National Cancer Institute

Zitieren

APA

Trautmann, T., Yakobian, N., & Nguyen, R. (2024). CAR T-cells for pediatric solid tumors: where to go from here?. Cancer and Metastasis Reviews. https://doi.org/10.1007/s10555-024-10214-6

Vancouver

Trautmann T, Yakobian N, Nguyen R. CAR T-cells for pediatric solid tumors: where to go from here?. Cancer and Metastasis Reviews. 2024. doi:10.1007/s10555-024-10214-6

BibTeX
@article{Trautmann2024,
  author = {Trautmann, Tina and Yakobian, Natalia and Nguyen, Rosa},
  title = {CAR T-cells for pediatric solid tumors: where to go from here?},
  journal = {Cancer and Metastasis Reviews},
  year = {2024},
  doi = {10.1007/s10555-024-10214-6}
}
Kostenlos starten →